09 April 2013| last updated at 10:52AM

"We have shown that it is possible to be genetically predisposed to being lazy," China's Xinhua news agency quoted study author Frank Booth, a professor from the Department of Physiology, School of Medicine, as saying.

"This could be an important step in identifying additional causes forobesity in humans," Booth said.

Booth and his fellow Michael Roberts were able to selectively breed rats that exhibited traits of either extreme activity or extreme laziness.

These rats indicate that genetics could play a role in exercise motivation, even in humans, according to the study published in the American Journal of Physiology: Regulatory, Integrative and Comparative Physiology.

"It would be very useful to know if a person is genetically predisposedto having a lack of motivation to exercise, because that could potentially makethem more likely to grow obese," said Booth.

Booth put rats in cages with running wheels and measured how much each rat willingly ran on their wheels during a six-day period.

They then bred the top 26 runners with each other and bred the 26 rats thatran the least with each other.

They repeated this process through 10 generations and found that the line of running rats chose to run 10 times more than the line of "lazy" rats.

Once the researchers created their "super runner" and "couch potato"rats, they studied the levels of mitochondria in muscle cells, compared body composition and conducted thorough genetic evaluations through RNA deep sequencing of each rat.

Read more:
Genetic link to laziness found in rats

Recommendation and review posted by Bethany Smith

Protein Synthesis
Genetics 4a Period 5 Tracy C. and Sage S.

By: Melissa Hero

See the article here:
Protein Synthesis - Video

Recommendation and review posted by Bethany Smith

How To Be A Great Parent (Spoof)
In this video, we teach you various ways on how to be great parent, it involves cooking and changing nappies! If you liked how we parent children please help...

By: TGFbro

See original here:
How To Be A Great Parent (Spoof) - Video

Recommendation and review posted by Bethany Smith

Hybridizing with extinct species: George Church at TEDxDeExtinction
George Church is Professor of Genetics, Harvard Medical School, Director of PersonalGenomes.org, providing the world #39;s only open-access information source fo...

By: TEDxTalks

Original post:
Hybridizing with extinct species: George Church at TEDxDeExtinction - Video

Recommendation and review posted by Bethany Smith

Supper with Sarah
via YouTube Capture.

By: Leota Fairview

Read the rest here:
Supper with Sarah - Video

Recommendation and review posted by Bethany Smith

Natural Science - Homo Erectus
"Will the real Homo erectus please stand up" by John Alsoszatai-Petho CWU, Department of Anthroplogy.

By: CentralWashU

Original post:
Natural Science - Homo Erectus - Video

Recommendation and review posted by Bethany Smith

I can #39;t sleep because I #39;m thinking too much
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

See more here:
I can't sleep because I'm thinking too much - Video

Recommendation and review posted by Bethany Smith

Hominid Paleobiology
Bones, Stones, and Genes: The Origin of Modern Humans. Hominid Paleobiology The fourth lecture of the Holiday Lectures on Science 2011 series by Howard Hughe...

By: FloatingJetsam

Read more from the original source:
Hominid Paleobiology - Video

Recommendation and review posted by Bethany Smith

Mendel #39;s Expections CAM
Ms. Chiao #39;s student teacher Ms. De Roos talks about exceptions to Mendel #39;s Laws of Inheritance.

By: Ava Chiao

Follow this link:
Mendel's Expections CAM - Video

Recommendation and review posted by Bethany Smith

Moderncraft S2 E20
Hey guys, sorry for the LONG delay, but I #39;ve been real busy in real life so I haven #39;t been able to upload. More Moderncraft is coming soon, I can assure you!...

By: Darasilverdragon

More here:
Moderncraft S2 E20 - Video

Recommendation and review posted by Bethany Smith

Rachel and her Fat Head

By: pdogg619

Link:
Rachel and her Fat Head - Video

Recommendation and review posted by Bethany Smith

Frame Genetics Claypan Boogieman

By: framegenetics

Go here to see the original:
Frame Genetics Claypan Boogieman - Video

Recommendation and review posted by Bethany Smith

CSA SmartGroup - Part 2 of Success Masterclass - Five Success Secrets in CSA.
Visit for more details - http://csasmartgroup.com/csa-success-masterclass-2013-video-series-part-2-five-success-machine-secrets-in-csa-and-how-to-master-them...

By: CSASmartGroup

See the article here:
CSA SmartGroup - Part 2 of Success Masterclass - Five Success Secrets in CSA. - Video

Recommendation and review posted by Bethany Smith

Pokemon Y 3DS - Update - New Mewtwo Form or Mewthree Confirmed
Subscribe to the Shows: http://www.youtube.com/show/pokemony3ds http://www.youtube.com/show/pokemonx3ds Follow Me On Twitter! https://twitter.com/#!/Cobanerm...

By: cobanermani456

Continue reading here:
Pokemon Y 3DS - Update - New Mewtwo Form or Mewthree Confirmed - Video

Recommendation and review posted by Bethany Smith

AMES, Iowa, April 8, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research (AACR) 2013 annual meeting. These data demonstrate that NLG919 potently inhibits the IDO pathway in vitro and in cell based assays, is orally bioavailable and has a favorable pharmacologic and toxicity profile. NLG919 is the second pipeline candidate from NewLink's IDO Pathway Inhibitor technology platform to be announced. This platform has also produced indoximod (NLG8189 or D1-MT) which is currently in Phase 2 clinical trials for the treatment of prostate cancer and metastatic breast cancer. Furthermore, NLG919 and indoximod show remarkable synergistic T-cell activation and antitumor activity.

"These data further support our view that IDO is a complex pathway with critical downstream immunomodulatory effects, and strategies that aim at multiple targets within this pathway may hold the most promise," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink. "We are encouraged by NLG919's anti-tumor and pharmacological properties and will continue to evaluate it, along with other IDO pathway inhibitors in our preclinical and clinical pipeline, as an innovative approach to harnessing the immune system to treat cancer."

In a poster presentation entitled "NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy," NewLink scientists presented preclinical data to demonstrate NLG919's on target anti-tumor effects as well as favorable oral bioavailability, pharmacokinetic and pharmacodynamic profiles.

The principal findings reported in the NLG919 study include:

About inhibition of the IDO pathway

IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4 and PD-1 which represent a potential breakthrough approach to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell function and enabling local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells expressing TAAs that might otherwise be recognized and attacked by the immune system. NewLink has a number of active programs directed at synthesizing IDO pathway inhibitors. These small-molecule, anti-tolerogenic product candidates are intended to counteract this key mechanism by which tumors evade immune-mediated destruction.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. NewLink's lead product candidate, algenpantucel-L (HyperAcute Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients. NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute Lung) in patients with non-small cell lung cancer. NewLink is developing indoximod, a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2,3)-dioxygenase, or IDO, pathway inhibitor technology. NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "target", "potential", "will", "could", "should", "seek", or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the prospects of algenpantucel-L, indoximod and our other HyperAcute product candidates and related clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including risks relating to: the initiation of clinical trials and the completion of enrollment; adverse general economic and industry conditions; and those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the period ended December 31, 2012, Form S-3 Registration Statement filed December 28, 2012 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink's views as of any date subsequent to the date of this press release.

See the original post here:
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting

Recommendation and review posted by Bethany Smith

Step Two of PMD #39;s System
Step Two: The PMD Calming Neuro Neutralizing Toner balances pH levels and renews essential skin cells for a more youthful appearance. Our innovative formula ...

By: pmd

Originally posted here:
Step Two of PMD's System - Video

Recommendation and review posted by Bethany Smith

Malaria and Sickle Cell Disease
Part of the Salsassin excerpt series.

By: blokcom

View original post here:
Malaria and Sickle Cell Disease - Video

Recommendation and review posted by Bethany Smith

Gene Therapy PSA

By: TravisBoyle1

Read the original post:
Gene Therapy PSA - Video

Recommendation and review posted by Bethany Smith

BAVUBUKA FOUNDATION - LUGA FLOW DREAMS EPISODE # 5

By: Bavubuka babaluku

Originally posted here:
BAVUBUKA FOUNDATION - LUGA FLOW DREAMS EPISODE # 5 - Video

Recommendation and review posted by Bethany Smith

ACGT today announced that seed money provided for innovative T-Cell immunotherapy cell and gene therapy research has led to two successful Clinical Trials for treatment of Acute Lymphoblastic Leukemia resulting in remissions in both children and adults who had no other hope of recovery.

Stamford, Connecticut (PRWEB) April 08, 2013

According to Michel Sadelain, MD, PhD, ACGT Scientific Advisory Council member and Research Fellow, and senior author of the Acute Lymphoblastic Leukemia study published March 21st in the journal Science Translational Medicine, This is a very exciting finding for patients and a major achievement in the field of targeted immunotherapy. Sadelain explained that these successful treatments would not have been possible had not been for the startup funding from ACGT. It wasnt easy to get funding to support such innovative, unproved therapies. The grant from ACGT was our first major grant to launch our T-cell program. Dr. Sadelain is the Director of the Center for Cell Engineering and Gene Transfer Expression Laboratory at Memorial Sloan-Kettering Cancer Center.

Dr. Sadelain, and Dr. Carl H. June, Perelman School of Medicine at the University of Pennsylvania, were each awarded $1 million in ACGT Clinical Investigator grants in 2004 to fund research using immune-mediated gene therapy for the treatment of lymphoma or leukemia. They were the first two Clinical Translational grants that ACGT awarded. Just last week, ACGT received 49 letters of intent, with a majority focused on T-cell therapy research, in response to its Request for Applications for 2013 Clinical Translational grants that will be awarded this Spring.

Dr. June, ACGT Scientific Advisory Council member and leader of the team that successfully treated two young leukemia patients, Emma Whitehead and Maddie Major, and seven other adult leukemia patients at the Abramson Cancer Center of the University of Pennsylvania (Penn) also commented on the cutting-edge research ACGT supported: "Funding was not available from the National Institutes of Health (NIH) for gene therapy (in 2004). ACGT was the first to be there, to say that cell and gene therapies can be a new platform therapy, and giving literally lifesaving grants to scientists who cannot get them from the federal system."

ACGT is the only not-for-profit in the U.S. solely dedicated to cancer cell and gene therapy treatments for all types of cancer. 100% of contributions go directly to research. ACGT has funded 41 grants since its founding in 2001 totaling almost $24 million to fund both basic research and clinical translation. ACGT's Scientific Advisory Council, comprised of 16 renowned physicians and researchers, conducts a rigorous review process. Seventeen ACGT funded research projects have been approved for human clinical trials, 11 of which are underway. To donate, please visit http://www.acgtfoundation.org or call 203.358.8000.

# # #

Press Contact:

Deborah Burns, 203.257.3163

deborah(at)burnscommunications(dot)net

Here is the original post:
ACGT Provides Seed Money for T-Cell Immunotherapy Cell and Gene Therapy Research; Successful Clinical Trials for ...

Recommendation and review posted by Bethany Smith

PARIS, April 8, 2013 /PRNewswire/ --

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a 32 million Series A financing.

The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). The lead product is expected to enter the clinic in 2013 in LHON patients.

Bernard Gilly, co-founder and CEO of GenSight is a successful bio-entrepreneur, was formerly CEO of Fovea Pharmaceuticals (which was acquired by sanofi-aventis in 2009), a partner at Sofinnova Partners and CEO of Transgene, a publicly traded gene therapy company. GenSight co-founder, Professor Jos-Alain Sahel, is Chairman of the Vision Institute in Paris. Botond Roska, a specialist in the structure and function of neural circuits at the FMI (Basel), has been pioneering the field of optogenetics. Jean Bennett, Professor of Ophthalmology, University of Pennsylvania, and also a co-founder of GenSight, has successfully conducted gene therapy trials to treat a rare retinal degeneration. The other co-founders of GenSight are Connie Cepko Professor of Genetics at Harvard (Boston), Ernst Bamberg Professor at The Max Planck Institute (Frankfurt), Luk Vandenberghe at the Schepens Eye Research Institute(Boston) and Serge Picaud at the Vision Institute (Paris).

Bernard Gilly commented: "Gene therapy is coming of age and ophthalmology is one of the most promising indications in particular because of the safety and efficacy demonstrated in certain trials. GenSight has a unique, proprietary approach to targeting the mitochondria in LHON developed by Dr Corral-Debrinsky and Jose Sahel at the Vision Institute, and exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients. Our outstanding links to leading ophthalmology physicians and scientists on both sides of the Atlantic, our strong link with the Foundation Fighting Blindness, our partnership with AFM/Genethon and our experienced management team are key to successfully moving our products through clinical developments to proof of efficacy."

"We are delighted to be working with GenSight and the other investors to assist the company in progressing its highly innovative technology and gene-based therapeutics towards the clinic. Gene therapy represents a new frontier in targeting ophthalmic diseases, and GenSight's expertise and capabilities are outstanding," said Florent Gros of Novartis Venture Fund, who will join the board of directors, along with Dr Genghis Lloyd-Harris (Abingworth) and Dr Guido Magni (Versant).

GenSight is based in Paris, France on the campus of the Vision Institute. Please visit our website http://www.gensight-biologics.com

Notes for Editors

About Novartis Venture Fund

The Novartis Venture Funds manages over $850 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. Our primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. The Funds invest for financial objectives at all stages, but prefers to invest in the early-stages of company development. With ten investment professionals located in Basel, Switzerland and Cambridge, MA the team has extensive experience in pharmaceutical R&D and venture capital.

Go here to see the original:
GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy

Recommendation and review posted by Bethany Smith

C6 spinal cord injury patient first time in water

By: allusv

The rest is here:
C6 spinal cord injury patient first time in water - Video

Recommendation and review posted by sam

Stem Cell Treatment for Spinal Cord Injury in Philippines
Stem Cell Treatment for Spinal Cord Injury Philippines.

By: stemcellregeneration

Read more:
Stem Cell Treatment for Spinal Cord Injury in Philippines - Video

Recommendation and review posted by sam

Tim Kamp on Advances in Regenerative Medicine
Dr. Tim Kamp is a professor of medicine at the University of Wisconsin School of Medicine and Public Health in Madison. Here he talks about some of the advan...

By: UWMedicine

Read this article:
Tim Kamp on Advances in Regenerative Medicine - Video

Recommendation and review posted by sam

Stem Cell Therapy for Pets - Teddy Before After
Amazing before and after footage of Teddy, an 11 year old dog who received stem cell therapy for his arthritis and received an unexpected benefit to his hear...

By: NewmanVets

See the article here:
Stem Cell Therapy for Pets - Teddy Before

Recommendation and review posted by Bethany Smith